07:42 AM EDT, 04/05/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that a phase 3 trial of Imfinzi showed "positive high-level results" and "clinically meaningful improvement" in the study's primary endpoints of overall survival and progression-free survival in patients with limited-stage small-cell lung cancer who had not progressed following concurrent chemoradiotherapy.

The 737 trial patients were randomized to receive a 1500mg fixed dose of Imfinzi, or durvalumab, with or without Imjudo 75mg every four weeks for up to four doses each, followed by Imfinzi every four weeks for up to 24 months.

The drug's safety profile was consistent with its known profie and no new safety signals were identified, the company said.

Imfinzi is already approved in the US, EU Japan, China and other countries for the treatment of extensive-stage small-cell lung cancer.

Price: 67.31, Change: -0.03, Percent Change: -0.04